Alnylam Pharmaceuticals, Inc. (ALNY) earnings on July 30, 2026

ALNY price around the earnings

205.48

Change: -28.3%

Start of the measured window End of the measured window

198.09 228.11 258.13 288.15 286.49

July 30, 2026

Price: green if it ends above the starting price; red if it ends below
Start of the measured window
End of the measured window
Market open
Starting price

Price series around the event

Prior thesis

Prior outlook: No statistical edge

Thesis published: 2026-07-30, 09:59 UTC
Results released: 2026-07-30, 12:01 UTC

Strong analyst upside and exceptional beat history, but recent PT cuts and negative trend strength create mixed setup.

Context analyzed before publication

Trend: Mixed trajectory with strong analyst upside and beat history, but recent negative trend strength and price target cuts.

Analysts

Evidence

Analyst consensus: Buy
Consensus average (1-5): 1.78
Analysts covering the stock: 23
Average price target: 432.04
Lowest price target: 285
Highest price target: 551
Upside to price target: 50.7%
Revenue growth: 96.4%
Forward EPS: 13.52
Trailing EPS: 3.98
Analyst moves in the last 60 days: 7

Strong buy: 7
Buy: 13
Hold: 7
Sell: 0
Strong sell: 0

Strong buy: 7
Buy: 13
Hold: 7
Sell: 0
Strong sell: 0

July 22, 2026 · JP Morgan: Maintains rating (Overweight → Overweight)
July 14, 2026 · B of A Securities: Maintains rating (Buy → Buy)
July 13, 2026 · Truist Securities: Maintains rating (Buy → Buy)
July 13, 2026 · HC Wainwright & Co.: Maintains rating (Buy → Buy)
July 10, 2026 · Morgan Stanley: Maintains rating (Equal-Weight → Equal-Weight)
June 29, 2026 · HC Wainwright & Co.: Maintains rating (Buy → Buy)
June 4, 2026 · HC Wainwright & Co.: Reiterates rating (Buy → Buy)

News and sentiment

Evidence

Sentiment

Sentiment: Constructive
Mention volume: Low
Normalized volume: 33%

News

Sources (9)

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $400 (opens in a new tab) — Benzinga
Alnylam Highlights Neuroscience Progress At AAIC 2026, Initiating Phase 2 APPlauDS Study Of Mivelsiran In Down Syndrome-Associated Alzheimer's While Completing cAPPricorn-1 Enrollment In CAA (opens in a new tab) — Benzinga
B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $410 (opens in a new tab) — Benzinga
Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $410 (opens in a new tab) — Benzinga
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $485 (opens in a new tab) — Benzinga
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $400 (opens in a new tab) — Benzinga
Aehr Test Systems, Lam Research, Applied Materials And Other Big Stocks Moving Higher On Thursday (opens in a new tab) — Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session (opens in a new tab) — Benzinga
Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket (opens in a new tab) — Benzinga

Technicals

Evidence

Price when the context was analyzed: 287.11
Average true range (ATR): 3.9%
Distance to 52-week high: -41.6%
14-day change (14d): +2.9%
30-day change (30d): -2.2%
30-day relative strength: +6.4%
QQQ change (30d): -8.6%
Nearest support: 283.99
Distance to nearest support: 1.1%
Nearest resistance: 287.13
Distance to nearest resistance: 0%
Volume accumulation ratio (14d / 46d): 1.21

Major: 283.99 (1.1% away, 0.28 ATR, 32 touches)
Mid: 281.86 (1.8% away, 0.47 ATR, 13 touches)
Major: 279.48 (2.7% away, 0.69 ATR, 32 touches)

Major: 287.13 (0% away, 0 ATR, 29 touches)
Mid: 290.6 (1.2% away, 0.31 ATR, 26 touches)
Major: 292.53 (1.9% away, 0.49 ATR, 22 touches)

Trends

Evidence

Average earnings surprise: +51.1%

April 30, 2026: actual EPS 1.99 vs estimate 1.47 (surprise +35.3%)
February 12, 2026: actual EPS 1.25 vs estimate 1.5 (surprise -16.5%)
October 30, 2025: actual EPS 2.9 vs estimate 1.75 (surprise +66.1%)
July 31, 2025: actual EPS 0.32 vs estimate 0.15 (surprise +119.6%)

Expected move

Implied move: +3.0%
Source: Options chain

Reactions over its last 20 earnings

Median move: 3%
75th percentile move: 6.9%
90th percentile move: 13.3%
Up / down moves: 9 / 11
Average up move: +4.5%
Average down move: -5.3%

Monitoring and close

What Alnylam Pharmaceuticals, Inc. reported

Status: Finished

Actual EPS	1.84
EPS estimate	2.14
EPS surprise	-14.2%

Alnylam reports Q2 2026 earnings. Needham maintains Buy but lowers price target to $357, reflecting pessimism after 2026 outlook cut.

Sources (11)

Needham Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $357 (opens in a new tab) — Benzinga
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks (opens in a new tab) — Benzinga
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
Alnylam Pharmaceuticals Q2 Earnings Call Highlights (opens in a new tab) — MarketBeat
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (opens in a new tab) — Zacks
Alnylam Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (opens in a new tab) — SeekingAlpha
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates (opens in a new tab) — Zacks
Alnylam Pharmaceuticals (NASDAQ:ALNY) Plunges After Q2 Revenue Miss and Lowered Full-Year Guidance (opens in a new tab) — ChartMill
Alnylam Pharmaceuticals Lowers FY2026 Sales Guidance from $5.300B-$5.800B to $5.275B-$5.725B vs $5.580B Est (opens in a new tab) — Benzinga
Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate (opens in a new tab) — Benzinga
Earnings per share: $1.84 vs $2.14 expected — below expectations. — Yahoo Finance

Pre-market second reading after the results

There is no second reading available for this event.

How the stock reacted

Consolidated: -28.2%
Max move: -30.9%

No verdict: the outlook took no direction, so there is nothing to score as a hit or a miss.